New Street Research - Bharti Airtel Limited (BHARTIARTL) Bharti Airtel (Buy, TP: INR1,400, +80%) Bharti lifts entry plan price by 57% in 7 more regions

Report

New Street Research

Chris Hoare

EUR 9453.00 For Business Accounts Only

Bharti Airtel (Buy, TP: INR1,400, +80%) Bharti lifts entry plan price by 57% in 7 more regions

Bharti has extended its 57% entry level tariff plan hike to 7 more regions. Brief thoughts and implications

25/01/2023 1 EN

Underlying

Bharti Airtel Limited

Bharti Airtel provides telecommunication systems and services to individuals and businesses in India with operations in 20 countries across Asia and Africa. In India, Co.'s product offerings include 2G, 3G and 4G wireless services, mobile commerce, fixed line services, high speed DSL broadband, IPTV, DTH, enterprise services including national & international long distance services to carriers. In the rest of the geographies, it offers 2G, 3G wireless services and mobile commerce. Co. had nearly 287 million customers across its operations at the end of Dec 2013.

See profile

INE397D01024 National Stock Exchange of India India

Provider

New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

Pan European Telecom Services and Cable
US Telecoms, Cable, Satellite and Towers
Global Emerging Market Telecoms
Japan Telecoms
Asian Internet
Pan European Healthcare
Global healthcare thematic research

We provide debt research on:

Pan European Telecom Services and Cable

See profile

Analysts

Chris Hoare

Other Reports on these Companies

New Street Research

Indian Mobile VIL – Nationalisation beckons, and implications for Bharti/RIL

With the company unlikely to have been able to engineer a meaningful recovery by the end of the moratorium on payments to the govt, and the stock trading below the level at which it can issue new shares, we see the most likely outcome now as creeping nationalisation. Bad for VIL, but great for Bharti and Jio. We discuss implications for Indus in a separate note out today.

EUR 9453.00

October 14, 2024 October 14, 2024 1 EN

New Street Research

Indian Telcos – Final AGR ruling and Vodafone IDEA Equipment deal – Our thoughts.

Yesterday, Vodafone Idea announced a INR 300bn (US$3.6bn) network equipment deal with Nokia, Ericsson and Samsung over the next three years to expand its 4G coverage and introduce 5G in key cities.

EUR 9453.00

September 23, 2024 September 23, 2024 1 EN

New Street Research

Indian Telcos Q1 FY25 review: Slower mobile with modest rise in margins

Indian mobile revenue rose steadily despite slowing this quarter due to softer ARPU trend. Both Bharti and Jio continue to take share from Vodafone Idea again. Mobile EBITDA kept ahead of topline with all three seeing YoY improvements in margin. Overall, Bharti remained ahead on both metrics.

EUR 9453.00

August 16, 2024 August 16, 2024 1 EN

TalkTalk H1 results: Guidance looks at risk

TalkTalk has reported its H1 results to August, albeit given the lack of an investor presentation, it is hard to decipher all the changes vs. their guidance at this stage, but we think the numbers are at the low end of any prior guidance. We are still also critically waiting for any disclosure on KPIs since February, but we think the risk is to the downside given Openreach disclosure.

EUR 9453.00

17h / 11m 17h / 11m 1 EN

Russell Waller

Russell Waller

Odido (T-Mobile NL) (Equal Weight) Q3 24: Positioned nicely for a possible IPO in 2025

SR trends continue to slide in aggregate, but Odido claimed that 2024 was always going to be a tough year for KPIs and SR (rebrand, T2 switch-off and commercial channel refurb), and talked confidently about the outlook for SR thanks to a mobile recovery (with a target of better postpaid adds going forward, so that it can take its “fair share of market growth”), and fixed gains.

EUR 9453.00

17h / 50m 17h / 50m 1 EN

Dominic Rose ... (+2)

Dominic Rose
Naresh Chouhan

EU Pharma 2025 Outlook - The Correction Was Due, Tread Carefully

In the aftermath of the H224 Healthcare correction, we look forward to 2025 with a more focused stock specific approach We show sector fundamentals have remained robust despite the correction. We see 4 key themes for the Pharma sector in 2025; 1) 2025 is a very strong year for important pipeline readouts, 2) The volume impact of Medicare Part D reform will dominate the narrative in H125 & continue to be a tailwind into 2026, 3) Margin expansion should be robust at a sector level, 4) Biotech M&A is likely to be materially higher than in 2024. As a result of these dynamics we change a number of...

EUR 4726.50

November 29, 2024 November 29, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Bharti Airtel (Buy, TP: INR1,400, +80%) Bharti lifts entry plan price by 57% in 7 more regions

Indian Mobile VIL – Nationalisation beckons, and implications for Bharti/RIL

Indian Telcos – Final AGR ruling and Vodafone IDEA Equipment deal – Our thoughts.

Indian Telcos Q1 FY25 review: Slower mobile with modest rise in margins

TalkTalk H1 results: Guidance looks at risk

Odido (T-Mobile NL) (Equal Weight) Q3 24: Positioned nicely for a possible IPO in 2025

EU Pharma 2025 Outlook - The Correction Was Due, Tread Carefully

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe